Sol J. Barer, Ph.D.

Sol J. Barer, Ph.D.

Lead Independent Director

Dr. Barer joined Celanese Research Company in 1974 and formed the Biotechnology Group that was spun out to form Celgene. Dr. Barer was Chairman and Chief Executive Officer from May 1, 2006 until June 16, 2010 and served as Executive Chairman from June 16, 2010 until December 31, 2010. Previously he was appointed President in 1993 and Chief Operating Officer in 1994.

Dr. Barer holds numerous professional awards, including the "Key Visionary Award" (Pontifical Council of Culture, Vatican and the Stem for Life Foundation), "Chairman's Award" (R&D Council of New Jersey), "Corporate Leadership Award" (Multiple Myeloma Research Foundation "Lifetime Achievement Award" (International Myeloma Foundation), "Outstanding Individual" (Biotech Meeting 2010), "Dream & Promise Award" (Children's Brain Tumor Foundation), "Odyssey Award" (Center for Medicine in the Public Interest), "Corporate Vision Award" (Gilda's Club), "Sparkle of Hope Award" (Community Hope), "Master Entrepreneur” (Ernst & Young), "Hall of Distinguished Alumni" (Rutgers University Alumni Federation), "Dr. Sol J. Barer Award for Vision, Innovation and Leadership" (BioNJ), "Science and Technology Industry Medal" (R&D Council of NJ), "Rutgers University Graduate School Distinguished Alumnus Award," "Winthrop-Sears Medal" (Chemists Club and the Chemical Heritage Foundation), "Albert Einstein Award in Life Sciences" (Global Capital Associates and Jerusalem Fund, Israel), and "DART/NYU Biotechnology Achievement Award" (Biotechnology Study Center of the NYU School of Medicine).

Dr. Barer was named one of "25 Leadership Legends of NJ" (NJBiz), "The 50 Most Powerful People in N.J. Health Care," inducted into the NJBiz Hall of Fame and named as one of NJ's top 10 scientists by New Jersey Business.

Dr. Barer serves as Chairman of the board of directors of the public companies Aevi Genomic Medicine, and Teva Pharmaceutical Industries, and the private company Centrexion. He is an advisor to biotechnology/medical companies, the Israel Biotech Fund and not for profit organizations.